In this cohort of 54 patients with NSCLC, irrespective of the availability of tissue EGFR testing, a plasma NGS test on its own would have provided clinically actionable mutation information in up to 37% of cases (20/54). Here, EGFR is linked to non-small cell lung carcinoma.